 |
Minimalna wpłata $50 Ekskluzywna promocja |
Nasz wynik |
0% prowizja |
Are you looking to buy Ultragenyx Pharmaceutical stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:RARE! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Ultragenyx Pharmaceutical stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Średnia wielkość
486,729 shs
KAPITAŁ RYNKOWY
$9.78 billion
Giełda Papierów Wartościowych
NASDAQ
Proszę kupić te akcje!
|
NAZWA
|
TICKER
|
PRZEMYSŁ
|
SEKTOR
|
VOLUME
|
KUP TERAZ TĘ AKCJĘ
|
|---|---|---|---|---|---|
|
NASDAQ:RARE
|
Preparaty farmaceutyczne
|
Medyczny
|
5,705 shs
|
Below is a quick guide on how to buy NASDAQ:RARE stocks safe, fast and around the world in less than five minutes.
Krok 1: Otworzyć rachunek w eToro – eToro is the best broker to buy Ultragenyx Pharmaceutical shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Krok 2: Załadować Państwa ID - Zgodnie z przepisami KYC eToro poprosi Państwa o przesłanie kopii paszportu lub prawa jazdy.
Krok 3: Wpłata środków - Proszę wpłacić trochę pieniędzy na swoje nowo utworzone konto eToro. Mogą Państwo wybrać pomiędzy przelewem bankowym, e-wallet lub kartą debetową/kredytową lub Paypal.
Krok 4: Buy Ultragenyx Pharmaceutical – Search for “”NASDAQ:RARE”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Ultragenyx Pharmaceutical stocks with 0% commission!.
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
15 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Ultragenyx Pharmaceutical in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Ultragenyx Pharmaceutical stock.
Wall Street analysts have given Ultragenyx Pharmaceutical a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Ultragenyx Pharmaceutical wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
2 |  | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
3 |  | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:RARE stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Ultragenyx Pharmaceutical stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Ultragenyx Pharmaceutical stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Ponieważ eToro jest platformą regulowaną, musi Pan wypełnić proces KYC, jest to standardowa procedura i zajmuje tylko kilka minut. Musi Pan przedstawić dowód tożsamości ze zdjęciem (paszport, prawo jazdy) oraz dowód adresu (rachunek za media, wyciąg z banku).
Po zarejestrowaniu się i zweryfikowaniu konta, należy wpłacić środki. eToro akceptuje karty kredytowe/debetowe, przelewy bankowe, a także e-wallety. Tak więc niezależnie od Państwa preferencji znajdzie się coś dla Państwa.
Now that you’ve funded your eToro account, just type “NASDAQ:RARE stocks" w pasku wyszukiwania na górze ekranu i nacisnąć "handel".
All that’s left is to buy some NASDAQ:RARE stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:RARE is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Ultragenyx Pharmaceutical stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its earnings results on Tuesday, October, 27th. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.15. The biopharmaceutical company had revenue of $81.47 million for the quarter, compared to analyst estimates of $55.18 million. Ultragenyx Pharmaceutical had a negative net margin of 119.19% and a negative trailing twelve-month return on equity of 50.69%.
View Ultragenyx Pharmaceutical’s earnings history.
Ultragenyx Pharmaceutical’s stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RARE stock has increased by 250.7% and is now trading at $159.02.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:RARE stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Ponad 95% środków klientów jest przechowywanych w trybie offline, w zimnym magazynie, co jest kluczowe dla każdego brokera, który zarządza Państwa aktywami. Niezależnie od tego, jak bezpieczna ma być platforma, zalecamy stosowanie 2FA, aby dodać dodatkową warstwę bezpieczeństwa do Państwa konta.
eToro oferuje użytkownikom szereg funkcji, aby mogli Państwo jak najszybciej zacząć inwestować. Mają Państwo stosunkowo unikalną funkcję copy trading, która pozwala na uzyskanie pasywnego dochodu poprzez odzwierciedlanie doświadczonych traderów, co pozwala szybko zacząć zarabiać i daje lepsze zrozumienie strategii stosowanych przez profesjonalistów. Dodatkowo eToro umożliwia użytkownikom inwestowanie w zarządzane portfele, przy czym zarządzany portfel to różne podobne aktywa zgrupowane razem, co pozwala na dywersyfikację konta i zmniejsza ewentualne ryzyko. Dla tych, którzy mają już doświadczenie w handlu, mogą Państwo inwestować na rynkach poza akcjami, ponieważ eToro pozwala użytkownikom na handel ETF-ami, towarami, kryptowalutami i indeksami. Jeżeli już inwestują Państwo poza przestrzenią giełdową, może to być bardzo przydatne, ponieważ pozwala to na zarządzanie wszystkimi Państwa inwestycjami w jednym miejscu.
15 Wall Street analysts have issued 12-month price objectives for Ultragenyx Pharmaceutical’s stock. Their forecasts range from $66.00 to $176.00. On average, they anticipate Ultragenyx Pharmaceutical’s stock price to reach $106.88 in the next twelve months. This suggests that the stock has a possible downside of 32.8%.
View analysts’ price targets for Ultragenyx Pharmaceutical or view top-rated stocks among Wall Street analysts.
Ultragenyx Pharmaceutical’s management team includes the following people:
Dr. Emil D. Kakkis M.D., Ph.D., Pres, CEO & Director (Age 61, Pay $1.23M)
Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 61, Pay $714.84k)
Mr. John Richard Pinion II, Chief Quality Operations Officer & Exec. VP of Translational Sciences (Age 55, Pay $690.65k)
Dr. Camille L. Bedrosian, Chief Medical Officer & Exec. VP (Age 68, Pay $755.15k)
Ms. Mardi C. Dier, Exec. VP & CFO (Age 57)
Mr. Theodore A. Huizenga, VP, Corp. Controller & Principal Accounting Officer (Age 50)
Mr. Dennis Karl Huang, Chief Technical Operations Officer & Exec. VP (Age 56)
Ms. Danielle Keatley, Sr. Director of Investor Relations & Corp. Communications
Ms. Karah Herdman Parschauer J.D., Gen. Counsel & Exec. VP (Age 43)
Mr. Ernie W. Meyer, Chief HR Officer & Exec. VP (Age 57)
CFD są złożonymi instrumentami i wiążą się z wysokim ryzykiem szybkiej utraty pieniędzy z powodu dźwigni finansowej. 68% kont inwestorów detalicznych traci pieniądze przy handlu CFD u tego dostawcy. Powinni Państwo rozważyć, czy rozumieją Państwo, jak działają kontrakty CFD i czy mogą sobie Państwo pozwolić na wysokie ryzyko utraty pieniędzy.
41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical’s employees.
Some companies that are related to Ultragenyx Pharmaceutical include BeiGene (BGNE), Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), CureVac (CVAC), UCB (UCBJF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX) and BioMarin Pharmaceutical (BMRN).
View all of RARE’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol “RARE.”
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
Ultragenyx Pharmaceutical’s stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.66%), First Trust Advisors LP (1.25%), Emerald Advisers LLC (0.37%), Emerald Mutual Fund Advisers Trust (0.36%), Pinnacle Associates Ltd. (0.26%) and California Public Employees Retirement System (0.25%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp and Theodore Alan Huizenga.
View institutional ownership trends for Ultragenyx Pharmaceutical.
RARE stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Pinnacle Associates Ltd., State of Wisconsin Investment Board, State of New Jersey Common Pension Fund D, XTX Markets LLC, Strs Ohio, Russell Investments Group Ltd., and SG Americas Securities LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical or view top insider-selling stocks.
RARE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., California Public Employees Retirement System, US Bancorp DE, and Calamos Advisors LLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical or or view top insider-buying stocks.
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Interactive Brokers Review, eToro Review, Przegląd DEGiro, AvaTrade Review, IG Markets Review, IC Markets Review, CMC Markets Review, Admiral Markets Review i wiele innych. Proszę przeczytać jedną z recenzji, aby dowiedzieć się wszystkiego o brokerze i zacząć kupować akcje już teraz.
One share of RARE stock can currently be purchased for approximately $159.02.
Ultragenyx Pharmaceutical has a market capitalization of $9.71 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.
Na Reportlab.org chcemy się upewnić, że mają Państwo wszystkie najbardziej istotne informacje na temat kupno akcji. Przynosimy Państwu najlepsze przewodniki po giełdzie z osobistymi opiniami, informacjami uzupełniającymi, opiniami o platformach, how to's i więcej. Chcą Państwo uzyskać inne informacje? Proszę zajrzeć na stronę Akcje OTC, Akcje NASDAQ, Akcje na NYSE, Akcje LON, Akcje FRA, Akcje ETR, Zapasy EPA, Akcje TSX lub Akcje Amex. Szukam bardziej szczegółowych informacji, takich jak 5g zapasy, akcje biotechnologiczne, akcje złota i inne informacje z naszego Reportlab.
How can you buy Ultragenyx Pharmaceutical stock on the internet?
You can easily buy Ultragenyx Pharmaceutical stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Inną opcją jest skorzystanie z usług regulowanego brokera, jak np. IC Markets lub Interactive Brokers. You can an account with these brokers and start buying or trading NASDAQ:RARE stocks in a safe and complete environment to trade in.
Where to buy Ultragenyx Pharmaceutical stock?
You will first want to find a licensed broker that supports NASDAQ:RARE stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:RARE stocks in a safe and complete environment.
Is NASDAQ:RARE stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:RARE stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Ultragenyx Pharmaceutical stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:RARE is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Ultragenyx Pharmaceutical stock.
How do you trade Ultragenyx Pharmaceutical stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Ultragenyx Pharmaceutical stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:RARE stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Ultragenyx Pharmaceutical stock?
To sell your NASDAQ:RARE stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Ultragenyx Pharmaceutical stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:RARE stock.
Stephen wie wiele o produktach finansowych, a w szczególności pasjonuje się rynkami giełdowymi i ich uczestnikami. Mamy nadzieję, że przedstawione informacje będą dla Państwa pomocne. Coś nie jest całkiem jasne? Proszę zostawić swoje pytania lub komentarze na dole strony.
| Nasz wynik ★★★★★ | |
| Nasz wynik ★★★★★ | |
| Nasz wynik ★★★★★ |
Newsletter
Najnowsze wiadomości
| |
Nasz wynik |
0% prowizja |
Paryska Giełda Papierów Wartościowych (EPA)
Wszystkie akcje EPA Więcej informacji Akcje EPA Czym jest Paryska Giełda Papierów Wartościowych (EPA)? Teraz
Dane o akcjach i kryptowalutach w czasie rzeczywistym
Powiadomienia, Porady & Nowości
Best Stocks & Crypto Guides
Recenzje brokerów i giełd online
Reportlab Finance jest stroną czysto informacyjną i w żadnym wypadku nie oznacza doradztwa inwestycyjnego. Wszystkie inwestycje niosą ze sobą ryzyko i mogą Państwo stracić wszystkie swoje inwestycje. Proszę nie inwestować pieniędzy, na których utratę nie mogą sobie Państwo pozwolić.
Reportlab Finance
38 Holburn Lane
Heckfield Green
IP21 0UB
Zjednoczone Królestwo
Copyright © 2022 Reportlab.Finance | Wszystkie prawa zastrzeżone.
